| Human herpesvirus 6 infection after hematopoietic cell transplantation: is routine surveillance necessary? | |
| | |
MedLine Citation:
|
PMID: 21549850 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Human herpesvirus 6 (HHV6) may be an important pathogen following allogeneic hematopoietic cell transplantation (HCT). We prospectively evaluated weekly HHV6 viremia testing after allogeneic HCT using a quantitative polymerase chain reaction (PCR)-based assay. HHV-6 viremia was detected in 46 of 82 (56%) patients at a median of 23 days post-HCT (range: day +10 to +168). More males (65% vs females 39%, P = .03) and recipients of umbilical cord blood (UCB 69% vs unrelated donor [URD], 46% vs sibling donor [20%] grafts, P = 0.01) reactivated HHV-6. Patients with HHV6 viremia had more cytomegalovirus (CMV) reactivation (26% vs 5.5%, P = .01) and unexplained fever and rash (23.9% vs 2.7%, P = .01) compared with patients without HHV6 viremia. High-level HHV6 (≥ 25,000 copies/mL) versus lower levels were associated with more culture-negative pneumonitis (72.7% vs 22.8%, P = .01). Twenty HHV6-positive patients were treated with foscarnet, ganciclovir, or cidofovir for HHV6 or other coexistent viruses. Within 2 weeks, HHV6 viremia resolved more commonly in treated (65%) than untreated patients (31%), P = .02. Survival at 3 months was similar in treated and untreated patients (90% vs 81%, P = .4). Survival at 3 and 6 months post-HCT were not affected by HHV6 positivity (3 months HHV6+ 85% vs 78%, P = .46; 6 months HHV6+ 70% vs 72%, P = .89) or by HHV6 level (3-month high level 73% vs 89%, P = .23; 6-month high level 64% vs 71%, P = .54). Neither the occurrence of HHV6, degree of viremia, nor use of antiviral drugs influenced short-term survival after HCT. |
| | |
Authors:
|
Brian C Betts; Jo-Anne H Young; Celalettin Ustun; Qing Cao; Daniel J Weisdorf |
Publication Detail:
|
Type: Clinical Trial; Journal Article Date: 2011-04-20 |
Journal Detail:
|
Title: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation Volume: 17 ISSN: 1523-6536 ISO Abbreviation: Biol. Blood Marrow Transplant. Publication Date: 2011 Oct |
Date Detail:
|
Created Date: 2011-09-19 Completed Date: 2012-02-20 Revised Date: 2012-02-27 |
Medline Journal Info:
|
Nlm Unique ID: 9600628 Medline TA: Biol Blood Marrow Transplant Country: United States |
Other Details:
|
Languages: eng Pagination: 1562-8 Citation Subset: IM |
Copyright Information:
|
Copyright © 2011 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved. |
Affiliation:
|
Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Antiviral Agents / administration & dosage Child Child, Preschool Cytomegalovirus Infections / drug therapy, etiology, mortality Disease-Free Survival Female Hematopoietic Stem Cell Transplantation* Herpesvirus 6, Human* Humans Infant Male Middle Aged Prospective Studies Roseolovirus Infections / blood, drug therapy, etiology, mortality* Sex Factors Siblings Survival Rate Transplantation, Homologous Unrelated Donors Viremia / drug therapy, mortality |
| Grant Support | |
ID/Acronym/Agency:
|
T32 CA009207-35/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antiviral Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Effect of several MAP compositions on the microbiological and sensory properties of Graviera cheese.
Next Document: Functional characterization of the oxaloacetase encoding gene and elimination of oxalate formation i...